H. Lundbeck A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public, Subsidiary

Established: 2000-01-01

Employees: 5.6K

Market Cap: -

Website: http://www.lundbeck.com

Clinical Trials

Binding and Effects of Lu AG06466 in the Brain of Healthy Men

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Lu AG06466

First Posted Date: 2022-02-02

Last Posted Date: 2022-09-09

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 8

Registration Number: NCT05219838

Locations: 🇺🇸
Invicro, LLC, New Haven, Connecticut, United States

A Study Investigating Lu AG06466 in Healthy Men

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]-Lu AG06466

First Posted Date: 2022-01-21

Last Posted Date: 2022-03-16

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 6

Registration Number: NCT05201092

Locations: 🇬🇧
LabCorp Clinical Research Unit Ltd, Leeds, United Kingdom

Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: Lu AG06466
Drug: Placebo

First Posted Date: 2022-01-04

Last Posted Date: 2022-07-12

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 24

Registration Number: NCT05177029

Locations: 🇯🇵
P-One Clinic, Keikokai Medical Corporation, Yokamachi Hachioji City, Tokyo, Japan

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Phase 3

Recruiting

Conditions: Migraine

Interventions: Drug: Eptinezumab

First Posted Date: 2021-12-20

Last Posted Date: 2025-01-09

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 600

Registration Number: NCT05164172

Locations: 🇮🇹
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy
🇷🇸
University Clinical Center Nis, Nis, Serbia
🇬🇧
Great Ormond Street Hospital, London, London, City Of, United Kingdom

and more 47 locations

A Study Investigating Lu AG22515 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Lu AG22515
Drug: Placebo
Drug: Immune System Activator

First Posted Date: 2021-11-26

Last Posted Date: 2023-08-28

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 58

Registration Number: NCT05136053

Locations: 🇺🇸
Frontage Clinical Research Inc, Secaucus, New Jersey, United States
🇺🇸
CenExel CNS, Long Beach, California, United States

A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Lu AG09222

First Posted Date: 2021-11-24

Last Posted Date: 2024-03-13

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 237

Registration Number: NCT05133323

Locations: 🇺🇸
Excell Research - ClinEdge - PPDS, Oceanside, California, United States
🇺🇸
UNISON Clinical Trials (Shahram Jacobs md inc.), Sherman Oaks, California, United States
🇺🇸
Allied Biomedical Research Institute, Miami, Florida, United States

and more 25 locations

A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen

Phase 1

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: Lu AG09222
Drug: Placebo

First Posted Date: 2021-11-19

Last Posted Date: 2022-10-27

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 30

Registration Number: NCT05126316

Locations: 🇬🇧
St Pancras Clinical Research, London, United Kingdom
🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom

A Study of Lu AF82422 in Participants With Multiple System Atrophy

Phase 2

Active, not recruiting

Conditions: Multiple System Atrophy

Interventions: Drug: Lu AF82422
Drug: Placebo

First Posted Date: 2021-11-03

Last Posted Date: 2024-12-27

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 64

Registration Number: NCT05104476

Locations: 🇺🇸
The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
🇺🇸
University of California - San Diego, La Jolla, California, United States
🇺🇸
UCSF Memory and Aging Center, San Francisco, California, United States

and more 16 locations

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

Phase 1

Terminated

Conditions: Focal Epilepsy

Interventions: Drug: Lu AG06466
Drug: Placebo

First Posted Date: 2021-10-18

Last Posted Date: 2022-11-09

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 1

Registration Number: NCT05081518

Locations: 🇺🇸
Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States

A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Eptinezumab Yeast Cell Line
Drug: Eptinezumab Mammalian Cell Line

First Posted Date: 2021-10-12

Last Posted Date: 2022-08-29

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 84

Registration Number: NCT05074459

Locations: 🇺🇸
Labcorp Clinical Research Unit, Inc., Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy